Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement☆

@inproceedings{Sethu2013ImmunoglobulinGA,
  title={Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement☆},
  author={Swaminathan Sethu and Karthik Govindappa and Paul D. Quinn and Meenu Wadhwa and Richard John Stebbings and Mike Boggild and Dean J Naisbitt and Ian David Kimber and Munir Pirmohamed and Kevin B Park and Jean G. Sathish},
  booktitle={Clinical immunology},
  year={2013}
}
A subset of patients with relapsing-remitting multiple sclerosis (RRMS) on therapy with interferon beta (IFNβ) develop neutralising anti-drug antibodies (ADA) resulting in reduced, or loss of, therapeutic efficacy. The aims were to characterise the relative contributions of anti-IFNβ antibody isotypes to drug neutralising activity, ability of these antibodies to cross-react with endogenous IFNβ, to form immune complexes and activate complement. IFNβ-specific ADA were measured in plasma from… CONTINUE READING
BETA